CR10534A - Inhibidores de prolil hidroxilasa - Google Patents

Inhibidores de prolil hidroxilasa

Info

Publication number
CR10534A
CR10534A CR10534A CR10534A CR10534A CR 10534 A CR10534 A CR 10534A CR 10534 A CR10534 A CR 10534A CR 10534 A CR10534 A CR 10534A CR 10534 A CR10534 A CR 10534A
Authority
CR
Costa Rica
Prior art keywords
prolil
hydroxylase inhibitors
pyrimidintrione
anemia
antagonists
Prior art date
Application number
CR10534A
Other languages
English (en)
Inventor
Kevin J Duffy
Duke M Fitch
Jian Jin
Ronggang Liu
Antony N Shaw
Kenneth Winggall
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38834409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10534(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CR10534A publication Critical patent/CR10534A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La invencion descrita en este documento se refiere a ciertos derivados de glicina, sustituidos en el N, de pirimidintriona de formula (I) que son antagonistas de HIF prolil hidroxilasas y son utiles para tratar enfermedades que se benefician de la inhibicion de esta enzima, siendo la anemia un ejemplo.
CR10534A 2006-06-23 2008-12-18 Inhibidores de prolil hidroxilasa CR10534A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80560206P 2006-06-23 2006-06-23

Publications (1)

Publication Number Publication Date
CR10534A true CR10534A (es) 2009-03-20

Family

ID=38834409

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10534A CR10534A (es) 2006-06-23 2008-12-18 Inhibidores de prolil hidroxilasa

Country Status (30)

Country Link
US (10) US8324208B2 (es)
EP (1) EP2037922B9 (es)
JP (1) JP5203361B2 (es)
KR (1) KR101411816B1 (es)
CN (1) CN101505752B (es)
AR (1) AR061570A1 (es)
AU (1) AU2007260837B2 (es)
BR (1) BRPI0713446B8 (es)
CA (1) CA2655491C (es)
CR (1) CR10534A (es)
DK (1) DK2037922T3 (es)
EA (1) EA018220B1 (es)
ES (1) ES2453100T3 (es)
HR (1) HRP20140306T1 (es)
IL (1) IL196070A (es)
JO (1) JO2934B1 (es)
MA (1) MA30526B1 (es)
MX (1) MX2009000165A (es)
MY (1) MY149861A (es)
NO (1) NO342019B1 (es)
NZ (1) NZ573698A (es)
PE (1) PE20080209A1 (es)
PL (1) PL2037922T3 (es)
PT (1) PT2037922E (es)
SG (1) SG174775A1 (es)
SI (1) SI2037922T1 (es)
TW (1) TWI394747B (es)
UA (1) UA100225C2 (es)
WO (1) WO2007150011A2 (es)
ZA (1) ZA200810602B (es)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1868616A2 (en) * 2005-03-29 2007-12-26 The University of Maryland, Baltimore Inhibitors for extracellular signal-regulated kinase docking domains and uses therefor
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
TWI394747B (zh) 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
EP2327696A1 (en) 2006-06-26 2011-06-01 Warner Chilcott Company, LLC Prolyl hydroxylase inhibitors and methods of use
GB0622472D0 (en) * 2006-11-10 2006-12-20 Addex Pharmaceuticals Sa Novel heterocyclic derivatives
WO2008076427A2 (en) 2006-12-18 2008-06-26 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
EP2097416B1 (en) 2006-12-18 2012-09-12 Amgen, Inc Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
ES2446418T3 (es) 2007-04-18 2014-03-07 Amgen, Inc Derivados de indanona que inhiben la prolil hidroxilasa
CA2683956C (en) 2007-04-18 2012-12-18 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
CA2685216C (en) 2007-05-04 2014-07-08 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
EP2155746A2 (en) 2007-05-04 2010-02-24 Amgen, Inc Diazaquinolones that inhibit prolyl hydroxylase activity
UA117800C2 (uk) * 2007-09-17 2018-10-10 Еббві Айрленд Анлімітед Компані Похідні урацилу або тиміну для лікування гепатиту с
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
ES2524883T3 (es) * 2008-03-18 2014-12-15 Merck Sharp & Dohme Corp. 4-Hidroxipirimidina-5-carboxamidas sustituidas
WO2009134750A1 (en) 2008-04-28 2009-11-05 Janssen Pharmaceutica Nv Benzoimidazoles as prolyl hydroxylase inhibitors
GB0809262D0 (en) 2008-05-21 2008-06-25 Isis Innovation Assay
US20110098324A1 (en) * 2008-06-25 2011-04-28 Brackley Iii James A Prolyl hydroxylase inhibitors
EP2334682B1 (en) 2008-08-20 2017-10-04 Fibrogen, Inc. Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
US20110144167A1 (en) * 2008-08-25 2011-06-16 Smithkline Beecham Corporation Prolyl Hydroxylase Inhibitors
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
US8937078B2 (en) 2009-02-10 2015-01-20 Janssen Pharmaceutica Nv Quinazolinones as prolyl hydroxylase inhibitors
AU2010228902A1 (en) * 2009-03-26 2011-10-06 Mapi Pharma Limited Process for the preparation of alogliptin
US20120046309A1 (en) * 2009-05-05 2012-02-23 Northwestern University Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis
ME01858B (me) * 2009-07-17 2014-12-20 Japan Tobacco Inc Jedinjenje triazolopiridina i njegovo dejstvo kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina
TWI500623B (zh) * 2009-10-13 2015-09-21 Torrent Pharmaceuticals Ltd 新穎稠合噻唑及噁唑嘧啶酮
PL2492266T3 (pl) 2009-10-21 2016-01-29 Daiichi Sankyo Co Ltd Pochodna 5-hydroksypirymidyno-4-karboksamidu
WO2011057121A1 (en) 2009-11-06 2011-05-12 Akebia Therapeutics Inc. Compositions and methods for treating colitis
AU2011289230B2 (en) 2010-08-13 2014-09-04 Janssen Pharmaceutica Nv 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors
EP2670750B1 (en) 2011-02-02 2016-09-14 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
KR101652606B1 (ko) 2011-06-06 2016-08-30 아케비아 테라퓨틱스 인코포레이티드 암 치료 방법으로서 저산소증 유도 인자-2 알파를 안정화시키기 위한 화합물 및 조성물
NO2686520T3 (es) 2011-06-06 2018-03-17
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
WO2013040790A1 (en) * 2011-09-23 2013-03-28 Merck Sharp & Dohme Corp. Substituted pyrimidines
EP2758058B1 (en) 2011-09-23 2017-04-26 Merck Sharp & Dohme Corp. Substituted pyrimidines
EP2758059B1 (en) 2011-09-23 2018-10-24 Merck Sharp & Dohme Corp. Substituted pyrimidines
WO2013040789A1 (en) * 2011-09-23 2013-03-28 Merck Sharp & Dohme Corp. Substituted pyrimidines
CN102432549B (zh) * 2011-09-28 2014-09-03 南通市华峰化工有限责任公司 一种抑制血管生成、肿瘤发生和增殖疾病的药物中间体1,3-二环己基巴比妥酸的制备方法
US9273034B2 (en) 2011-10-25 2016-03-01 Janssen Pharmaceutica Nv Meglumine salt formulations of 1-(5,6-dichloro-1H-benzo[D]imidazol-2-yl)-1H-pyrazole-4-carboxylic acid
WO2013070908A1 (en) * 2011-11-09 2013-05-16 Fibrogen, Inc. Therapeutic method
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
SG11201500720WA (en) 2012-07-30 2015-04-29 Taisho Pharmaceutical Co Ltd Partially saturated nitrogen-containing heterocyclic compound
CN103146720B (zh) * 2013-03-01 2014-12-03 河北博伦特药业有限公司 一种具有高转化率的反式-4-羟基-l-脯氨酸羟化酶改造基因及其应用
SG11201509998WA (en) 2013-06-13 2016-01-28 Akebia Therapeutics Inc Compositions and methods for treating anemia
JP2016536362A (ja) * 2013-11-08 2016-11-24 バイエル ファーマ アクチエンゲゼルシャフト 置換されているウラシル類及びそれらの使用
WO2015067651A1 (de) 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituierte uracile als chymase inhibitoren
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
JP5975122B2 (ja) * 2014-01-29 2016-08-23 大正製薬株式会社 ［（４−ヒドロキシ−２−オキソ−１，２，５，６−テトラヒドロ−３−ピリジニル）カルボニル］グリシン化合物の結晶形及びそれらの製造方法
EP3107542B1 (en) 2014-02-19 2019-05-01 Aerpio Therapeutics, Inc. Process for preparing n-benzyl-3-hydroxy-4-substituted-pyridin-2-(1h)-ones
CN104151254A (zh) * 2014-07-25 2014-11-19 南通市华峰化工有限责任公司 一种制备1，3-双环己基巴比妥酸的方法
ES2898476T3 (es) 2014-09-02 2022-03-07 Sunshine Lake Pharma Co Ltd Compuesto de quinolona y uso del mismo
WO2016054805A1 (en) * 2014-10-10 2016-04-14 Merck Sharp & Dohme Corp. Substituted pyrimidines as inhibitors of hif prolyl hydroxylase
WO2016054806A1 (en) * 2014-10-10 2016-04-14 Merck Sharp & Dohme Corp. Substittued pyridine inhibitors of hif prolyl hydroxylase
JP2018039733A (ja) * 2014-12-22 2018-03-15 株式会社富士薬品 新規複素環誘導体
CN107427503A (zh) 2015-01-23 2017-12-01 阿克比治疗有限公司 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途
CN106146395B (zh) 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
TWI836883B (zh) 2015-04-01 2024-03-21 美商阿克比治療有限公司 用於治療貧血之組合物及方法
US10401548B2 (en) * 2015-09-24 2019-09-03 Intel Corporation Integrated antenna with display uniformity
SG11201802777XA (en) 2015-10-14 2018-05-30 X Therma Inc Compositions and methods for reducing ice crystal formation
JP6325139B2 (ja) * 2016-03-02 2018-05-16 ネルファルマ・エッセ・エッルレ・エッレ カルムスチンの安全で効率的な製造方法
CN113004271A (zh) 2017-05-09 2021-06-22 杭州安道药业有限公司 吲哚嗪衍生物及其在医药上的应用
CN111518038B (zh) * 2017-05-26 2022-04-05 深圳市塔吉瑞生物医药有限公司 一种取代的嘧啶三酮化合物及包含该化合物的组合物及其用途
WO2019052133A1 (zh) 2017-09-15 2019-03-21 苏州科睿思制药有限公司 Gsk1278863的晶型及其制备方法和制药用途
CA3097219A1 (en) 2018-05-09 2019-11-14 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
CN109134356A (zh) * 2018-06-18 2019-01-04 苏州盖德精细材料有限公司 一种中间体2-氨基吡啶-4-甲醇的制备方法
EP3880663A1 (en) 2018-11-15 2021-09-22 Teva Pharmaceuticals International GmbH Solid state forms of daprodustat and process for preparation thereof
CN113811530B (zh) * 2019-07-03 2022-07-19 南京明德新药研发有限公司 作为糜酶抑制剂的嘧啶酮类化合物及其应用
CN112752577B (zh) * 2019-08-20 2023-07-07 深圳仁泰医药科技有限公司 Daprodustat的晶型及其制备方法和用途
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
EP4138825A1 (en) 2020-04-20 2023-03-01 Akebia Therapeutics Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
JP7797425B2 (ja) 2020-06-19 2026-01-13 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド ダプロデュスタットを含んでなる処方物
CN114671878B (zh) * 2020-12-25 2023-08-04 广东东阳光药业有限公司 取代的含氮双环化合物及其用途
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
WO2022179967A1 (en) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat for treating covid-19 in a hospitalized subject
CN115260108B (zh) * 2021-04-30 2025-10-21 广东东阳光药业股份有限公司 一种酸的共晶及其制备方法
CN117999069A (zh) 2021-05-27 2024-05-07 凯克斯生物制药公司 柠檬酸铁的儿科调配物
US20240228443A1 (en) * 2021-06-18 2024-07-11 Glaxosmithkline Intellectual Property (No.2) Limited Novel manufacturing method of daprodustat and precursors thereof
IT202100020591A1 (it) 2021-07-30 2023-01-30 Dipharma Francis Srl Preparazione di un intermedio di un agente per il trattamento dell'anemia
IT202100020609A1 (it) 2021-07-30 2023-01-30 Dipharma Francis Srl Metodo di preparazione di agente adatto per il trattamento dell'anemia
IT202200008693A1 (it) 2022-04-29 2023-10-29 Dipharma Francis Srl Metodo per la preparazione e la purificazione di un agente per il trattamento dell'anemia
WO2023006986A1 (en) 2021-07-30 2023-02-02 Dipharma Francis S.R.L. Method for preparing and purifying an agent suitable for treating anemia
WO2024022998A1 (en) 2022-07-26 2024-02-01 Inke, S.A. Process for preparing daprodustat and cocrystals thereof
GB202211231D0 (en) 2022-08-02 2022-09-14 Glaxosmithkline Ip No 2 Ltd Novel formulation
GB202301059D0 (en) 2023-01-25 2023-03-08 Univ Oxford Innovation Ltd PHD inhibitors
WO2024247913A1 (ja) 2023-05-26 2024-12-05 富士フイルム株式会社 積層体、貼合体、画像表示システム、および、貼合体の製造方法
WO2024256830A1 (en) 2023-06-14 2024-12-19 Cipla Limited Daprodustat polymorphs and processes for preparation thereof
WO2025051160A1 (zh) * 2023-09-08 2025-03-13 北京华益健康药物研究中心 用于治疗或预防冠状病毒感染的3cl蛋白酶抑制剂及其用途
WO2025101966A1 (en) * 2023-11-08 2025-05-15 Northwestern University Hif-2alpha targeting for enhanced transplant tolerance

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE118208T1 (de) 1989-10-16 1995-02-15 Chiroscience Ltd Chirale azabicycloheptanone und verfahren zu ihrer herstellung.
DK0650960T3 (da) * 1993-11-02 1997-09-01 Hoechst Ag Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler.
AU5316900A (en) 1999-06-03 2000-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
WO2003024955A2 (en) 2001-09-18 2003-03-27 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
CN102552262A (zh) * 2001-12-06 2012-07-11 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
US7180893B1 (en) 2002-03-22 2007-02-20 Juniper Networks, Inc. Parallel layer 2 and layer 3 processing components in a network router
ATE359791T1 (de) * 2002-08-13 2007-05-15 Warner Lambert Co Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US7323475B2 (en) * 2003-06-06 2008-01-29 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and methods of use thereof
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
EA013427B1 (ru) 2004-03-15 2010-04-30 Такеда Фармасьютикал Компани Лимитед Ингибиторы дипептидилпептидазы
JP2007277096A (ja) 2004-07-15 2007-10-25 Astellas Pharma Inc フェネチルニコチンアミド誘導体含有医薬
US7718624B2 (en) 2004-09-01 2010-05-18 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors
CN101394843A (zh) 2005-06-06 2009-03-25 菲布罗根公司 使用HIFα稳定剂的改进的贫血治疗
EP1947943A4 (en) 2005-10-21 2009-11-25 Univ Alabama SMALL MOLECULAR INHIBITORS OF HIV-1 CAPSIDE FORMATION
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
CL2007001829A1 (es) 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
TWI394747B (zh) * 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
US20090011051A1 (en) 2006-09-28 2009-01-08 Roth Mark B Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds
US20100003190A1 (en) 2006-12-08 2010-01-07 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN)
CL2008000065A1 (es) 2007-01-12 2008-09-22 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia.
WO2019052133A1 (zh) 2017-09-15 2019-03-21 苏州科睿思制药有限公司 Gsk1278863的晶型及其制备方法和制药用途
EP3880663A1 (en) 2018-11-15 2021-09-22 Teva Pharmaceuticals International GmbH Solid state forms of daprodustat and process for preparation thereof

Also Published As

Publication number Publication date
EP2037922B9 (en) 2017-08-23
DK2037922T3 (en) 2014-03-24
PE20080209A1 (es) 2008-05-15
TWI394747B (zh) 2013-05-01
AR061570A1 (es) 2008-09-03
BRPI0713446B1 (pt) 2019-10-29
JP2009541351A (ja) 2009-11-26
NO20090202L (no) 2009-03-23
BRPI0713446B8 (pt) 2021-05-25
JO2934B1 (en) 2015-09-15
US20150315157A1 (en) 2015-11-05
EA200970050A1 (ru) 2009-06-30
HRP20140306T1 (hr) 2014-05-09
US8324208B2 (en) 2012-12-04
KR101411816B1 (ko) 2014-06-24
CA2655491C (en) 2016-09-06
EP2037922A4 (en) 2012-08-22
SG174775A1 (en) 2011-10-28
US10336711B2 (en) 2019-07-02
AU2007260837A1 (en) 2007-12-27
WO2007150011A3 (en) 2008-03-27
EP2037922B1 (en) 2014-01-22
MA30526B1 (fr) 2009-06-01
JP5203361B2 (ja) 2013-06-05
KR20090030321A (ko) 2009-03-24
US8557834B2 (en) 2013-10-15
ES2453100T3 (es) 2014-04-04
PL2037922T3 (pl) 2014-06-30
PT2037922E (pt) 2014-04-14
US20200157055A1 (en) 2020-05-21
AU2007260837B2 (en) 2013-07-04
US20210347740A1 (en) 2021-11-11
US20160297772A1 (en) 2016-10-13
US20100113444A1 (en) 2010-05-06
WO2007150011A2 (en) 2007-12-27
US20230227414A1 (en) 2023-07-20
TW200815364A (en) 2008-04-01
MY149861A (en) 2013-10-31
EA018220B1 (ru) 2013-06-28
HK1130671A1 (en) 2010-01-08
CN101505752A (zh) 2009-08-12
US20180305323A1 (en) 2018-10-25
US10035779B2 (en) 2018-07-31
EP2037922A2 (en) 2009-03-25
MX2009000165A (es) 2009-01-23
US8815884B2 (en) 2014-08-26
SI2037922T1 (sl) 2014-04-30
NZ573698A (en) 2012-02-24
IL196070A0 (en) 2009-09-01
US11643397B2 (en) 2023-05-09
UA100225C2 (uk) 2012-12-10
CA2655491A1 (en) 2007-12-27
US20140336383A1 (en) 2014-11-13
BRPI0713446A2 (pt) 2012-03-06
NO342019B1 (no) 2018-03-12
US20140024666A1 (en) 2014-01-23
WO2007150011A8 (en) 2008-07-10
US20130072487A1 (en) 2013-03-21
ZA200810602B (en) 2010-10-27
IL196070A (en) 2015-05-31
CN101505752B (zh) 2012-12-05

Similar Documents

Publication Publication Date Title
CR10534A (es) Inhibidores de prolil hidroxilasa
CL2022001670A1 (es) Inhibidores de proteínas kras mutantes
MX2009007548A (es) Derivados de glicina n-sustituidos: inhibidores de hidroxilasa.
WO2007103905A3 (en) Prolyl hydroxylase inhibitors
WO2007136990A3 (en) Prolyl hydroxylase inhibitors
CR10186A (es) Inhibidores de 11-beta-hsd1
EA201000915A1 (ru) Ингибиторы пролилгидроксилазы
ECSP077223A (es) Indazoles utiles en el tratamiento de enfermedades cardiovasculares
NO20084334L (no) Farmasoytiske sammensetninger
ECSP066893A (es) Inhibidores de proteínas de apoptosis (iap)
CL2011001333A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
BRPI0710521A2 (pt) quinazolinas para inibição de pdk1
ECSP099078A (es) Derivados de amino-piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
NO20081636L (no) FAP - inhibitorer
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
EA201000920A1 (ru) Ингибиторы пролилгидроксилазы
CR11618A (es) Inhibidores macrocíclicos de serina proteasa
CL2007002166A1 (es) Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
HN2009001165A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
ATE527253T1 (de) Pyrimidin-substituierte benzimidazolderivate als proteinkinasehemmer
CO6220968A2 (es) Inhibidores heterociclicos de la aspartil proteasa
ATE479687T1 (de) Kinaseinhibitoren
UY30297A1 (es) Inhibidores de la quinasa c-fms-i
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct